All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 1

home / case-based-peer-perspectives / egfr-nsclc-case-1

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Molecular Testing for NSCLC

EP. 1: Molecular Testing for NSCLC

October 11th 2016

Watch

How is Molecular Testing Used to Select Upfront Therapy in Patients with EGFR Mutations?

EP. 2: How is Molecular Testing Used to Select Upfront Therapy in Patients with EGFR Mutations?

October 11th 2016

Watch

CASE 1: A 44-year-old Female Diagnosed with Relapsed Stage IV Adenocarcinoma

EP. 3: CASE 1: A 44-year-old Female Diagnosed with Relapsed Stage IV Adenocarcinoma

October 11th 2016

Watch

What is the Rationale for Repeat Molecular Testing at Progression?

EP. 4: What is the Rationale for Repeat Molecular Testing at Progression?

October 11th 2016

Watch

How Will the Availability of Liquid Biopsy Change the Paradigm of Genetic Testing in the Setting of Metastatic Lung Cancer?

EP. 5: How Will the Availability of Liquid Biopsy Change the Paradigm of Genetic Testing in the Setting of Metastatic Lung Cancer?

October 11th 2016

Watch

How Has the Availability of Osimertinib Changed the Treatment Paradigm for Repeat Molecular Testing at Progression?

EP. 6: How Has the Availability of Osimertinib Changed the Treatment Paradigm for Repeat Molecular Testing at Progression?

October 11th 2016

Watch

Safety and Efficacy Data for Osimertinib

EP. 7: Safety and Efficacy Data for Osimertinib

October 11th 2016

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.